Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized Phase 2 trial of AZD3241 in multiple system atrophy
2014-004902-13Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verdiperstat in multiple system atrophy (MSA) (3 arms), sponsored by AstraZeneca. Primary endpoints: [11C]PBR28 binding to translocator protein as measured by PET and Safety and tolerability. Started Dec 2014; status: completed.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2014-004902-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004902-13.